Information Provided By:
Fly News Breaks for May 16, 2019
May 16, 2019 | 08:41 EDT
Baird analyst Madhu Kumar raised his price target for Iovance Biotherapeutics to $34 from $29 and maintained an Outperform rating, citing increased tumor-infiltrading lymphocyte technology conviction on ASCO abstracts in cervical cancer and metastatic melanoma. The abstracts for Phase 2 data for TIL technology increases his conviction in Iova's TILs, particularly in cervical cancer, the analyst says in a research note.
News For IOVA From the Last 2 Days
There are no results for your query IOVA